A simple viral infection contracted in youth or middle age may be the hidden trigger for Parkinson's disease that emerges decades later. Researchers at Texas A&M University have created the first animal model proving that a naturally occurring virus can cause the exact brain damage and movement problems seen in Parkinson's patients, without requiring toxic chemicals or genetic engineering.

How Does a Virus Cause Parkinson's Brain Damage?

The study used a mouse virus called Theiler's murine encephalomyelitis virus (TMEV) to demonstrate what scientists call the "hit-and-run" theory. This concept suggests that a virus contracted years or even decades earlier can trigger a slow-burning inflammatory cascade in the brain that gradually destroys dopamine-producing neurons, the cells essential for smooth movement.

Within just seven days of viral exposure, the researchers confirmed that TMEV had infected the dopamine-producing brain cells. By one month after infection, these vital neurons were completely destroyed. The team validated this loss using specialized tests that measure dopamine function, comparing 13 infected animals to 14 healthy controls.

The physical consequences were striking. When researchers tested the animals' motor skills using a standard assessment called the pole test, infected animals were significantly slower than healthy controls. Even more telling, this slowness persisted at week 20 when the study ended, suggesting the damage was permanent.

Walking patterns also deteriorated. Using a specialized treadmill that evaluated over 100 distinct factors involved in walking, balance, and motor function, researchers confirmed that the viral infection caused the same gait degradation seen in human Parkinson's patients.

Why Does This Research Matter for Parkinson's Patients?

Parkinson's disease affects more than 10 million people worldwide, making it the second most common neurodegenerative disorder after dementia. The disease destroys the ability to move smoothly, causing tremors, rigidity, balance problems, and cognitive decline. Yet its origins have remained mysterious for decades.

Previous animal models relied on either artificial gene modifications or injections of highly toxic chemicals to mimic Parkinson's. While useful, these approaches don't capture how the disease actually develops in humans. As one researcher explained, not everyone exposed to these chemicals develops Parkinson's, so the models miss the complexity of real disease progression.

"The toxic-exposure models are useful for studying Parkinson's, but not all people who are exposed to chemicals go on to develop Parkinson's, so these models cannot show all the ways a disease as complex as Parkinson's actually begins or develops over time in people," said Candice Brinkmeyer-Langford, a neurodegenerative disease expert with the Texas A&M University School of Public Health.

Candice Brinkmeyer-Langford, Neurodegenerative Disease Expert, Texas A&M University School of Public Health

The TMEV model changes this by showing that a common, non-toxic viral infection alone can trigger the full spectrum of Parkinson's pathology. This validates what neuroscientists have long suspected but couldn't prove: that everyday viruses may be the environmental trigger for late-life neurodegeneration.

What Viruses Might Be Involved?

The research doesn't identify a single culprit virus. Instead, it demonstrates a principle that likely applies to multiple viruses. Scientists have long known that different viruses can cause entirely different diseases depending on a person's genetics and immune response.

• Epstein-Barr Virus: Causes mononucleosis in most people but may contribute to cancer or multiple sclerosis in others
• SARS-CoV-2: Primarily attacks the lungs but can also damage the heart and brain
• Theiler's Virus: In this study, triggered Parkinson's-like brain damage in mice, suggesting other common viruses might do the same in humans

This means a person might contract a common respiratory virus in their 30s or 40s, recover completely, and then decades later develop Parkinson's as that initial infection's delayed consequence.

What Comes Next for Parkinson's Research?

The Texas A&M team plans to use this validated TMEV model to accelerate Parkinson's research in several directions. They will test the viral model directly against traditional chemical models to understand which approach better mimics human disease. They're also searching for early warning signs and biological markers that could identify people at risk before symptoms appear.

Another priority is mapping the specific immune-cell signaling loops that transform a common infection into a fatal brain condition. Understanding these pathways could eventually lead to treatments that interrupt the cascade before dopamine neurons are destroyed.

"The clock is ticking, since the rapidly aging global population means the number of people with Parkinson's is expected to jump significantly," noted Brinkmeyer-Langford.

Candice Brinkmeyer-Langford, Neurodegenerative Disease Expert, Texas A&M University School of Public Health

The study involved collaboration across Texas A&M's veterinary medicine, biomedical sciences, and neuroscience departments, bringing together expertise in animal models, viral pathology, and brain disease. This multidisciplinary approach may be essential for translating findings from mice to human patients.

For the millions living with Parkinson's today, this research offers hope that future treatments might target the viral trigger or the inflammatory cascade it sets off, potentially slowing or stopping disease progression. For those who may be at risk, it underscores the importance of managing overall health and immune function, though more research is needed to identify which viral exposures pose the greatest risk.